SKI O 703

Drug Profile

SKI O 703

Alternative Names: mesylate salt of SKI-O-592; SKI-O-703

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oscotec
  • Class Anti-inflammatories; Antirheumatics; Small molecules
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Phase I Idiopathic thrombocytopenic purpura; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 02 Sep 2016 Phase-I clinical trials in Idiopathic thrombocytopenic purpura in USA (PO) before September 2016
  • 02 Sep 2016 Phase-I clinical trials in Systemic lupus erythematosus in USA (PO) before September 2016
  • 19 Apr 2016 SKI O 703 is available for licensing as of 19 Apr 2016. http://eng.kddf.org/Tasks/?mode=view&TaskId=102&p=1
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top